Real-World study reveals how long lung fibrosis patients stick with treatment
NCT ID NCT06485635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in France tracked over 10,000 people with idiopathic pulmonary fibrosis to see how long they continued taking antifibrotic drugs (nintedanib or pirfenidone). The goal was to measure the percentage still on treatment after 30 months and identify factors linked to stopping early. The study did not test new treatments but aimed to improve real-world care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nintedanib and Pirfenidone
- What this could lead to
- If successful, this could help doctors understand why some patients stop treatment and find ways to improve long-term care for lung fibrosis.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures persistence, not whether the drugs work or are safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinityx
Boulogne-Billancourt, 92100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care